The Line Between Staffing and Safety
Nurse staffing shortages and hospital labor strikes have shifted from episodic disruptions to structural features of healthcare delivery risk. Over ...
The Borderland Before Diabetes
Prediabetes and early metabolic risk identification have re‑entered clinical and policy conversation over the past two weeks as new biomarker ...
The Taxonomy of Advantage
In the Calendar Year 2027 Medicare Advantage and Part D Advance Notice, the Centers for Medicare & Medicaid Services projected ...
Eligibility Is the New Gatekeeper
Medicaid policy shifts centered on work requirements and eligibility verification have returned to the foreground of federal and state health ...
The Pap Smear’s Successor Problem
HPV and cervical cancer screening innovation has re-entered the clinical and investment spotlight over the past two weeks as new ...
When Oversight Becomes a Market Force
House oversight activity directed at health insurer practices and alleged exchange fraud has become a sustained focus of policy and ...
The Architecture of Attrition
The head of a major health system can depart with little more notice than a quarterly earnings release, and yet ...
The Staffing Equation That Doesn’t Balance
Healthcare labor market pressure has moved from cyclical complaint to structural condition, and over the past two weeks sustained search ...
The Breach Is the Business Model
Healthcare cybersecurity and health system data risk management have moved from technical afterthought to board-level agenda item, driven by ransomware ...
The GLP‑1 Reckoning
Consumer and clinician debate around glucagon-like peptide‑1 receptor agonists and related incretin therapies has intensified across search trends, professional forums, ...
The Diagnostic Gold Rush
Genetic testing has moved from clinical edge case to reimbursement flashpoint, and recent oversight reporting on Medicare Part B spending ...
Refusal to File
In early 2026, the U.S. Food and Drug Administration issued a refusal-to-file letter declining to review a major manufacturer’s biologics ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more